HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC Board Includes Sale In Menu For Financial, Strategic Overhaul

This article was originally published in The Tan Sheet

Executive Summary

The wellness and nutritional product manufacturer and retailer's board has "commenced a review of a wide range of strategic and financial alternatives to increase shareholder value." The board's review will include looking at accelerating the firm's already-launched refranchising initiative.

You may also be interested in...



GNC 'Broken Business' Repair: Single-Tier Pricing, Free Loyalty Program

Interim CEO Robert Moran says "we found … a badly broken business in need of change" since he took the helm in July. The broken parts include a loyalty program not driving sales; inconsistent and confusing pricing; and point-of-sale checkout failures.

Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel